Still we and others have previously validated different proteins in independent AD cohorts using custom PEA assays (e.g., those relevant for the current study such as ITGB2, DDC, CLEC5A, PARK7) [2], as well as different single immunoassays (e.g., DDC, THOP1, sTREM1, MIF, GFAP, NfL) [11–13], supporting the validity of the results obtained with PEA proteomics. This evidence concerns the gene CLEC5A and Alzheimer disease.